Archive
-
2021/08/24Allist awarded “Emerging Medical Innovator in China 2021” by PHIIC
-
2021/08/10Care-free Furmonertinib for Ningbo
-
2021/07/28Develop first-in-class Drug against King of Cancer
-
2021/07/26Furmonertinib Listed in Beijing Supplemental Medical Insurance Program
-
2021/07/23Du Jinhao, Chairman of Allist, was Invited to Give a Speech at the Forum for Scientific & Innovative Enterprises hosted by Li Qiang, Secretary of Shanghai Municipal Party Committee
-
2021/07/15Furmonertinib provides whole-year care for Zhanjiang people: zero deductible and 80% reimbursement for eligible ones
-
2021/07/02The first subject enrolled in the FORWARD research on Furmonertinib-based adjuvant treatment
-
2021/06/30Breaking News! 800 million USD plus equity share
-
2021/06/11Never forget why we started, never stop where we pursue
-
2021/05/09Furmonertinib added to Qindao e-Insurance coverage rolled out on Mother’s Day